ReviewEuropean endocrinology2015
Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.
Review in European endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Preparation and property evaluation of oral colon targeted protein delivery system with sodium alginate and chitosan.Scientific reports · 2025Article
- Diverting organic waste from landfills via insect biomanufacturing using engineered black soldier flies (Hermetia illucens).Communications biology · 2024Review
- Atomic resolution structure of full-length human insulin fibrils.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Advanced Electroanalysis for Electrosynthesis.ACS organic & inorganic Au · 2024Review
- Biosimilars in Oncology: Latest Trends and Regulatory Status.Pharmaceutics · 2022Review
- An NMR-Based Similarity Metric for Higher Order Structure Quality Assessment Among U.S. Marketed Insulin Therapeutics.Journal of pharmaceutical sciences · 2020Article
- Oral delivery of novel human IGF-1 bioencapsulated in lettuce cells promotes musculoskeletal cell proliferation, differentiation and diabetic fracture healing.Biomaterials · 2020Article
- Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019Article
- Nanomedical Relevance of the Intermolecular Interaction Dynamics-Examples from Lysozymes and Insulins.ACS omega · 2019Article
- Production costs and potential prices for biosimilars of human insulin and insulin analogues.BMJ global health · 2018Article
- Recombinant Human Insulin in Global Diabetes Management - Focus on Clinical Efficacy.European endocrinology · 2017Review
- Recombinant Human Insulins - Clinical Efficacy and Safety in Diabetes Therapy.European endocrinology · 2016Review
- Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2015Article
- Biosimilar insulins: Informed choice for South Asia.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant human insulin was one of the first products of biotechnology. It was developed in response to the need for a consistent and sufficient worldwide supply. Recombinant human insulin replaced the animal insulins and semisynthetic insulins obtained by modification of animal insulins. Bioequivalence studies were required for regulatory approval. Three reference products were independently established during these procedures: Humulin® (Eli Lilly and Co), Novolin® (NovoNordisk) and Insuman® (Sanofi). Numerous brand names have been used during the commercial development of recombinant human insulin formulations. In this review, three current brand names are used for consistent identification. Human insulin for Humulin and Insuman are produced by fermentation in bacteria (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.